Identifying which immune cells to harvest and expand for personalized cancer therapy has long been the bottleneck separating promising immunotherapy concepts from reliable clinical outcomes. A new method that uses two proteins expressed on the outer surface of CD4+ T cells could dramatically streamline that selection process, with implications for adoptive cell transfer therapies in solid tumors and beyond.
Published in PNAS, this research identifies a dual-marker signature — the adhesion G protein-coupled receptor ADGRG1 (also known as GPR56) and the co-stimulatory molecule CD86 — as a reliable surface readout for distinguishing genuinely antitumor CD4+ helper T cells from the broader, heterogeneous pool of immune cells found in human tumors. Rather than relying on intracellular cytokine assays or functional activation screens that require cell destruction, detecting ADGRG1 and CD86 simultaneously on the cell surface enables live-cell sorting and downstream therapeutic use. The cohort and effect-size specifics, including how accurately this combination outperforms existing markers, are detailed in the full publication.
This finding lands at an important inflection point in cellular immunotherapy. CD4+ T cells have historically played second fiddle to CD8+ cytotoxic T cells in cancer immunotherapy design, yet accumulating evidence — including landmark adoptive transfer cases in metastatic colorectal and breast cancers — confirms their independent tumor-killing capacity. The central challenge has been identification without destruction. ADGRG1 has prior literature linking it to tissue-resident immune phenotypes, while CD86 is better known as a B-cell and dendritic-cell activation marker; its expression on CD4+ T cells in the tumor microenvironment is a less-explored angle. The combination is conceptually novel. Key limitations to consider: human cancer studies at this stage are often small, and whether these markers generalize across tumor types and patient populations requires prospective validation. Still, if replicated, this surface-marker approach could meaningfully accelerate the manufacturing pipeline for personalized T-cell therapies.